Wellington Management Group LLP Purchases 148,310 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Wellington Management Group LLP raised its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 47.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 462,864 shares of the biopharmaceutical company's stock after acquiring an additional 148,310 shares during the period. Wellington Management Group LLP owned about 0.30% of Ocular Therapeutix worth $4,027,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Atlas Capital Advisors LLC acquired a new position in shares of Ocular Therapeutix in the second quarter valued at $34,000. Amalgamated Bank increased its holdings in Ocular Therapeutix by 37.9% in the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock valued at $37,000 after buying an additional 1,481 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Ocular Therapeutix by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 1,015 shares in the last quarter. Algert Global LLC bought a new position in shares of Ocular Therapeutix during the 2nd quarter worth about $69,000. Finally, Capital Performance Advisors LLP bought a new position in shares of Ocular Therapeutix during the 3rd quarter worth about $70,000. Institutional investors own 59.21% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on OCUL. Scotiabank started coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.71.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of the company's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the transaction, the insider now owns 269,059 shares of the company's stock, valued at approximately $2,424,221.59. This represents a 1.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.50% of the stock is currently owned by company insiders.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock traded down $0.58 on Wednesday, reaching $8.44. The company's stock had a trading volume of 723,966 shares, compared to its average volume of 1,773,309. The business's fifty day moving average price is $10.04 and its 200 day moving average price is $8.56. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -6.39 and a beta of 1.19. Ocular Therapeutix, Inc. has a twelve month low of $3.63 and a twelve month high of $11.77.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.